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Prognostic value of assessment of stool and serum 
IL-1b, IL-1ra and IL-6 concentrations in children with 
active and inactive ulcerative colitis
Andrzej Wędrychowicz1, Przemysław Tomasik2, Andrzej Zając3, Krzysztof Fyderek1
A b s t r a c t
Introduction: Interleukin-1b (IL-1b), interleukin-1 receptor antagonist (IL-1ra) 
and interleukin-6 (IL-6) contribute to the pathogenesis of ulcerative colitis 
(UC). The aim of our study was to evaluate the serum and stool IL-1b, IL-1ra 
and IL-6 concentrations as potential prognostic factors in children with UC. 
Material and methods: Thirty-eight children with UC (20 active, 18 inac-
tive) and 14 healthy controls were prospectively included in the study. IL-1b, 
IL-1ra and IL-6 concentrations were measured in serum and stool super-
natants at inclusion to the study using ELISA immunoassays. The children 
were followed up over 5 years, and at each follow-up clinical disease activity, 
quantity and severity of relapses, nutritional status, endoscopic and histo-
pathologic activity, disease complications and the treatment regimen were 
evaluated. 
Results: In children with active and inactive UC who had relapsed during 
a 5-year follow-up period compared to the non-relapse groups we found 
significantly increased serum IL-1b (1.34 vs. 0.98 pg/ml, p < 0.05, and 1.02 
vs. 0.68 pg/ml, p < 0.01, respectively,) and IL-1ra (718.0 vs. 453.2 pg/ml, 
p < 0.05, and 567.4 vs. 365.1 pg/ml, p < 0.01, respectively). Additionally, 
in children who had experienced complications during a 5-year follow-up 
period we observed significantly increased serum and stool IL-1b (p < 0.05) 
and serum IL-1ra (p < 0.01) compared to the group without complications.
Conclusions: We concluded that serum IL-1b and IL-1ra and to a lesser ex-
tend stool IL-1b concentrations may be useful prognostic factors in children 
with active and inactive UC over a short-term follow-up period, which may 
help to identify children that require more aggressive therapy due to an in-
creased risk of relapse or complications resulting from UC. 
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Introduction
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) 
and Crohn’s disease (CD), are chronic diseases of the gastrointestinal 
tract, characterized by relapsing intestinal inflammation. Both UC and CD 
share similar clinical symptoms including chronic diarrhea, abdominal 
pain, weight loss and growth failure [1].
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Although the exact cause of IBD is still un-
known, there is evidence to support an essential 
role of the mucosal immune system in the initia-
tion and perpetuation of inflammation [2]. Recent 
studies have identified bacterial microflora-de-
rived antigens which adversely affect immunolog-
ical reactions in the gut [3, 4].
Pro-inflammatory cytokines produced by the 
cells of the immune system, such as tumor necro-
sis factor (TNF)-α, interleukin (IL)-1b, IL-1 receptor 
antagonist (ra) and IL-6 play a major role in the 
pathogenesis of IBD [5]. 
Results from previous studies suggest that an 
imbalance of IL-1b and IL-1ra concentrations plays 
a  crucial role in the early stages of IBD develop-
ment. The elevated plasma and tissue IL-1ra con-
centrations observed in patients with IBD suggest 
that IL-1ra may be responsible for downregulating 
inflammatory pathways [6]. The IL-1ra/IL-1 ratio 
has been found to be negatively correlated with 
IBD activity, and remains constant in uninvolved 
areas of CD and in control patients [7]. The muco-
sal imbalance of intestinal IL-1 and IL-1ra observed 
in IBD patients suggests that insufficient produc-
tion of endogenous IL-1ra may contribute to the 
pathogenesis of chronic gut inflammation [8].
Elevated serum IL-1b, IL-1ra and IL-6 concen-
trations have been reported in patients with ac-
tive UC and CD in multiple studies [9–11]. Similar 
observations have been made in studies which 
investigated the mucosal and fecal concentrations 
of IL-1b, IL-1ra and IL-6 in children and adults with 
active and inactive IBD [12–15]. 
Ulcerative colitis is a  chronic disease charac-
terized by relapses and complications, which alter 
the clinical course of the disease in addition to 
impairing the development of the child. Various 
factors may be responsible for UC relapse, includ-
ing infections, diet and lack of patient compliance. 
However, in the majority of cases it is not possible 
to identify the specific factor that triggered the 
disease relapse, and therefore it is not possible to 
prevent the relapse. Before the clinical symptoms 
of relapse are visible in the patient, multiple im-
munological and inflammatory reactions probably 
take place, and tracking these changes could be 
used for clinical predictive purposes. 
Ulcerative colitis can also be associated with 
different complications, during both short- and 
long-term patient follow-up periods, including 
hemorrhage, toxic megacolon, malnutrition and 
hepatobiliary and thromboembolic diseases. While 
treatment complications often develop early af-
ter disease onset, they can develop much later in 
some patients.
Nevertheless, there is a  lack of knowledge re-
garding prognostic factors that could be used to 
predict relapses or complications in chronic relaps-
ing diseases such as UC. This would allow for the 
optimization of treatment regimens and could be 
used to improve the clinical care of UC patients, 
in addition to their improving developmental out-
comes and quality of life.
The aim of this study was to evaluate serum 
and stool IL-1b, IL-1ra and IL-6 concentrations for 
their potential use in the prediction of relapses 
and complications resulting from UC in children.
Material and methods
Thirty-eight children with UC (20 active, at the 
time of onset of the disease, and 18 inactive, at 
the remission of the disease) and 14 healthy chil-
dren (controls) were prospectively included in the 
study. The active UC group consisted of 10 boys 
and 10 girls with a mean age of 10.6 years (range: 
2–15 years), and the inactive UC group consisted 
of 8 boys and 10 girls with a  mean age of 11.7 
years (range: 3.5–18 years). The active UC group 
consisted of newly diagnosed patients with clinical 
symptoms of UC, while the inactive UC group con-
sisted of patients diagnosed previously, without 
any symptoms of UC at the time of inclusion. The 
mean time of UC duration in the inactive UC group 
was 1.5 years (range: 0.5–2 years). The control 
group consisted of 7 boys and 7 girls with a mean 
age of 11 years (range: 3.5–16 years), without any 
pathological gastrointestinal tract symptoms. 
The diagnosis of UC was based on the Porto cri-
teria [16]. The UC children were followed up over 
a 5-year period from their enrollment in the study. At 
each follow-up they were evaluated for clinical dis-
ease activity, number and severity of relapses, nutri-
tional status, complications and treatment regimen. 
The clinical activity of UC was assessed accord-
ing to the modified Truelove-Witts clinical activity 
index, and clinical remission was defined as a to-
tal score of < 2 points [17, 18]. 
As there is currently no established standard 
definition of UC relapse, we defined a  clinical 
relapse of UC as the worsening of symptoms or 
the emergence of new symptoms that increased 
the modified Truelove-Witts clinical activity index 
score of > 2 points, as well as if the treatment 
regimen required modification, which included in-
creasing the doses of current drugs or introducing 
new ones.
During the follow-up period, relapse was ob-
served in a  total of 14 patients in the active UC 
group after a median 1.6 years of follow-up (range: 
1.1–1.8 years) and 7 patients from the inactive 
UC group after a  median 2.7 years of follow-up 
(range: 1.8–3.6 years of follow-up). Complications 
of UC were diagnosed in 5 children in the active 
UC group after a  median 1.8 years of follow-up 
(range: 0.5–3.2 years) (severe hemorrhage – 2 pa-
tients, vein thrombosis – 1 patient, liver disease – 
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2 patients) and 6 children in the inactive UC group 
after a median 2.6 years of follow-up (range: 1.6–
4.5 years) (malnutrition – 2 patients, osteoporosis 
– 2 patients, liver disease – 2 patients) over the 
5-year follow-up period. 
An improvement in nutritional status was de-
fined as an increase in body weight, the Cole index 
and BMI z-score of the patient, when compared to 
their baseline values. The Cole index was defined 
as the weight/height-for-age2, and consisted of 
the squared weight/height ratio, expressed as the 
percentage of this ratio as calculated for a refer-
ence child of the same age and sex [19]. 
Control ileocolonoscopy was performed on ev-
ery relapsed patient. Their endoscopic activity was 
assessed according to the Mayo UC endoscopic 
score index, and their histopathological activity 
was assessed according to the histopathological 
Gupta score index [20, 21].
The initial pharmacological treatment used for 
children in the active UC group consisted of 5-ami-
no salicylates (sulphasalazine and mesalazine), 
antibiotics (metronidazole) and steroids (predni-
sone), depending on the activity of the disease. In 
the inactive UC group the pharmacological treat-
ment included 5-amino salicylates (sulphasalazine 
and mesalazine) and thiopurines (azathioprine) as 
maintenance therapy [22–24].
IL-1b, IL-1ra and IL-6 concentrations were mea-
sured in serum and stool supernatants at inclu-
sion in the study using commercial quantitative 
ELISA immunoassays (R&D Systems, USA). 
Stool supernatants were prepared from fresh 
stool samples (20–50 g), which were collected and 
weighed in sterile containers after the individual 
had defecated. The stool samples were then emul-
sified in an equal volume of phosphate buffered 
saline (PBS, pH 7.2) containing protease inhibitors 
(soy trypsin inhibitor and phenylmethylsulfonyl 
fluoride, 1 mg/ml; Gibco, USA) and centrifuged at 
10,000 rpm for 20 min. Afterwards, the superna-
tant was filtered through a 0.45 µm micropore fil-
ter (Millipore, USA), collected and stored at –70°C 
until the ELISA assays [25–27].
The study protocol was approved by the Jagiel-
lonian University Bioethical Committee. Informed 
consent was obtained from all patients enrolled 
in the study, either from the legal guardian of pa-
tients aged under 16 years or from the patients 
themselves if aged over 16 years.
Statistical analysis
Statistical analyses were performed using Sta-
tistica 10 software (StatSoft Inc., Tulsa, OK, USA) 
using the Mann-Whitney U test, Wilcoxon signed-
rank test and Spearman’s rank correlation test. All 
results were presented as the median values and 
ranges, and p < 0.05 was considered to be statis-
tically significant in all analyses.
Results
The serum and stool IL-1b, IL-1ra and IL-6 
concentrations were significantly higher and the 
IL-1ra/IL-1b ratio was lower in the active UC group 
compared to the inactive UC and control groups 
(p < 0.05) at the beginning of the study. In the in-
active UC group both the serum and stool sample 
IL-1b, IL-1ra and IL-6 concentrations and IL-1ra/
IL-1b ratios were comparable to controls (Table I).
Table I. Serum and stool IL-1b, IL-1ra and IL-6 concentrations and IL-1ra/IL-1b ratio in active and inactive UC and 
control groups at the beginning of the study
Parameter Active UC group (n = 20) Inactive UC group (n = 18) Control group (n = 14)
IL-1b [pg/ml]:
Serum 1.05 (0.38–2.69)* 0.87 (0.39–1.9) 0.33 (0.11–1.0)
Stool 393.7 (55.5–855)* 9.1 (5.2–21.3) 13.5 (6.9–22.6)
IL-1ra [pg/ml]:
Serum 532.1 (135.4–898.4)* 418.1 (205–946.9) 322.5 (183–737)
Stool 4950.3 (910.7–6525)* 406.9 (131.3–835) 678.5 (242–1570)
IL-1ra/IL-1b ratio:
Serum 450.4 (267.4–1287)* 535.0 (225–1108) 856 (367–2233)
Stool 10.8 (6–32)* 45.7 (9.2–76.6) 47.5 (14–115)
IL-6 [pg/ml]:
Serum 5.8 (1.3–10.7)* 2.1 (0.37–7.5) 2.7 (0.54–6)
Stool 13 (4.6–31.8)* 11.3 (1.6–29.9) 14.6 (9.9–33)
Results are presented as median values and ranges. *P < 0.05 when compared to inactive UC and control group.
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In the active UC group the serum IL-1b and IL-1ra 
concentrations were significantly higher and IL-
1ra/IL-1b ratios were lower in patients who had 
relapsed during the 5-year follow-up period com-
pared to patients who had not relapsed (Table II). 
Serum IL-1b concentrations were also signifi-
cantly higher in children who had relapsed in the 
active UC group and these patients had severe en-
doscopic activity (n = 9) compared to those with 
moderate and mild endoscopic activity (n = 11) as 
assessed at the disease onset (p < 0.05). 
We observed higher serum and stool IL-1b 
(p < 0.05 for both sample types) and serum IL-1ra 
concentrations (p < 0.01) in patients in the active 
UC group who had experienced complications 
during the 5-year follow-up period compared to 
the group without any complications (Figure 1).
We did not find any statistically significant 
differences in IL-1b, IL-1ra or IL-1ra\IL-1b ratio in 
stool between relapsing and non-relapsing UC pa-
tients. 
For patients in the inactive UC group, we found 
that serum IL-1b and IL-1ra concentrations were 
higher and the IL-1ra/IL-1b ratio was lower in 
patients who had relapsed during the 5-year fol-
low-up period compared to the non-relapsing 
group (Table III).
Serum IL-1b and IL-1ra concentrations were 
higher (p < 0.003 and p < 0.005, respectively) and 
the stool IL-6 concentration was lower (p < 0.05) 
in patients in the inactive UC group who had expe-
rienced complications within the 5-year follow-up 
period (6 children) compared to the group without 
complications. 
We did not find any statistically significant dif-
ferences or correlations between relapsing and 
non-relapsing UC patients regarding the clinical, 
endoscopic and histopathological activity of UC, 
disease location, disease duration, nutritional sta-
tus or used treatment (Tables IV, V).
There were no statistically significant differ-
ences or correlations in IL-1b, IL-1ra and IL-6 
concentrations and the IL-1ra/IL-1b ratio in the 
active and inactive UC groups for clinical and his-
topathological activity scoring indexes, nutritional 
status, number and severity of relapses, compli-
Table II. Serum IL-1b, IL-1ra and IL-6 concentrations and IL-1ra/IL-1b ratio in relapsing and non-relapsing patients 
during a 5-year follow-up period for active UC group
Parameter Relapsing group (n = 14) Non-relapsing group (n = 6) P-value
IL-1b [pg/ml] 1.34 (1.04–2.69) 0.98 (0.38–1.36) 0.05
IL-1ra [pg/ml] 718.0 (675.2–898.4) 453.2 (135.4–654.9) 0.05
IL-1ra/IL-1b ratio 377.6 (267.4–576.9) 514.3 (387.67–1287) 0.05
IL-6 [pg/ml] 7.48 (3.50–10.7) 4.74 (1.3–7.47) 0.23
Results are presented as median values and ranges.
Figure 1. Concentrations of IL-1b in serum (A), 
stool (B) and IL-1ra in serum (C) in active ulcer-
ative colitis (UC) patients who had experienced 
complications during the 5-year follow-up period 
compared to the group without any complications. 
Data are expressed as median values and ranges. 
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Table III. Serum IL-1b, IL-1ra and IL-6 concentrations and IL-1ra/IL-1b ratio in relapsing and non-relapsing patients 
during a 5-year follow-up period for inactive UC group
Parameter Relapsing group (n = 7) Non-relapsing group (n = 11) P-value
IL-1b [pg/ml] 1.02 (0.43–1.90) 0.68 (0.39–1.02) 0.01
IL-1ra [pg/ml] 567.4 (358.3–946.9) 365.1 (205–520.9) 0.01
IL-1ra/IL-1b ratio 506.3 (225–840.9) 684.0 (261.7–1108) 0.05
IL-6 [pg/ml] 2.57 (1.98–7.5) 1.89 (0.37–3.87) 0.18
Results are presented as median values and ranges.
Table IV. Differences between relapsing and non-relapsing patients of active UC group regarding activity of the 
disease and used treatment
Parameter Relapsing group (n = 14) Non-relapsing group (n = 6) P-value
Clinical activity (Truelove-Witts index) 5 (3–10) 4 (3–9) 0.79
Endoscopic activity (Mayo score) 2 (1–3) 2 (1–2) 0.48
Histopathological activity (Gupta score) 2 (1–3) 2 (1–2) 0.54
Disease location:
Left-sided 15% 16% 0.68
Pancolitis 85% 84% 0.74
Disease duration [weeks] 6 (3–16) 5 (2.5–20) 0.86
Nutritional status:
BMI z-score –0.3 (–0.7 – 0.3) –0.5 (–0.7 – 0.1) 0.37
Cole index 85% (80–92%) 83% (78–88%) 0.28
Treatment:
5-ASA 30% 32% 0.82
5-ASA and antibiotics 15% 16% 0.88
5-ASA and antibiotics and steroids 55% 52% 0.76
Data are presented as median values and ranges. BMI – body mass index, 5-ASA – 5 aminosalicylic acid.
Table V. Differences between relapsing and non-relapsing patients of inactive UC group regarding activity of the 
disease and used treatment
Parameter Relapsing group (n = 7) Non-relapsing group (n = 11) P-value
Clinical activity (Truelove-Witts index) 1 (0–3) 1 (0–2) 0.83
Endoscopic activity (Mayo score) 2 (1–3) 1 (1–2) 0.36
Histopathological activity (Gupta score) 2 (1–3) 1 (1–2) 0.45
Disease location:
Left-sided 15% 9% 0.43
Pancolitis 85% 91% 0.78
Disease duration [years] 1.3 (0.5–2) 1.6 (0.8–2) 0.82
Nutritional status:
BMI z-score –0.2 (–0.6 – 0.4) –0.4 (–0.7 – 0.2) 0.52
Cole index 87% (82–98%) 85% (81–93%) 0.58
Treatment:
5-ASA 15% 30% 0.73
5-ASA and thiopurines 85% 70% 0.81
Data are presented as median values and ranges. BMI – body mass index, 5-ASA – 5 aminosalicylic acid.
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cations and treatment regimen during the 5-year 
follow-up period. 
Discussion
Ulcerative colitis is a chronic intestinal disorder 
characterized by relapses with exacerbation of in-
testinal symptoms. However, despite appropriate 
maintenance therapy, it is impossible to predict 
and prevent flare-ups in clinical practice. 
The prevention and early treatment of relapses 
are essential in the medical care of UC patients. 
This could potentially reduce the number and se-
verity of relapses, increase the quality of life of UC 
patients and reduce the financial costs associated 
with treatment.
Numerous previous studies have aimed to de-
termine the prognostic factors associated with 
UC relapses, including analyzing acute phase pro-
teins, fecal occult blood tests or stool calprotectin 
concentration. 
Kuriyama et al. examined the feasibility of 
predicting UC relapses using the quantitative 
immunochemical fecal occult blood test in adult 
patients with inactive UC over a  20-month fol-
low-up period. They observed an increase in fecal 
hemoglobin concentration in 20% of patients 2 to 
4 weeks before any clinical symptoms of relapse 
[28]. The fecal occult blood test is cheap and easy 
to perform, but it is not specific for UC, and pos-
itive results could be associated with infections, 
menstruation or colorectal cancer. 
Fecal calprotectin is the most frequently used 
predictive factor for IBD in clinical practice due 
to its high correlation with endoscopic and histo-
pathologic activity [29, 30]. Tibble et al. found that 
elevated concentrations of fecal calprotectin in 
patients with a quiescent course of IBD had 90% 
sensitivity and 83% specificity for predicting re-
lapse [31]. A study by Yamamoto et al. evaluated 
the predictive ability of a single point fecal calpro-
tectin and lactoferrin assessment for relapse in 
adult patients with inactive UC. They followed up 
a group of UC patients for 12 months and found 
that increased concentrations of both fecal calpro-
tectin and lactoferrin were associated with clinical 
relapse of the disease [32]. However, fecal calpro-
tectin was not found to be correlated with IBD 
activity in patients after surgical resections, while 
fecal lactoferrin was higher in patients with UC 
compared to those with CD, and was considered 
to be a superior marker for UC [29].
OruÇ et al. investigated a  group of 45 newly 
diagnosed IBD patients, and compared the diag-
nostic value of assessment of serum acute phase 
reactant proteins, including C-reactive protein, 
procalcitonin and erythrocyte sedimentation rate 
(ESR). They found that C-reactive protein was the 
most sensitive and useful marker of IBD activity 
when compared to other acute phase reactants. 
The authors of the study suggested that procalci-
tonin and ESR have no clinical value in the assess-
ment of disease activity in IBD [33].
In our study, we focused on cytokines as im-
munological mediators as they play a key role in 
determining the nature of immunomodulation 
during inflammatory responses and may be help-
ful in clinical assessment in different immune-re-
lated diseases [5, 34]. Cytokines are related to the 
synthesis and secretion of immunological media-
tors such as leukotrienes, prostaglandins and re-
active oxygen metabolites, and these are associ-
ated with the severity of inflammatory reactions. 
Nevertheless, cytokines may also be involved in 
immunological reactions resulting in perpetuation 
of inflammation in the colon leading to relapses 
and complications. Long-lasting stimulation and 
continuous production of immunological medi-
ators (e.g. ILs, TNF) may result in involvement of 
another organ and extraintestinal manifestations 
(skin, joint or liver diseases) or impaired metabolic 
reactions (osteoporosis, malnutrition).
Therefore, we speculated that altered concen-
trations of these cytokines may affect disease ac-
tivity [35].
We used a similar method to previous studies 
for the single point stool assessment of the immu-
nological mediators IL-1b, IL-6 and IL-1ra, which 
have been confirmed to contribute to the patho-
genesis of UC. For a  more sensitive assessment 
we assessed the IL concentrations in both serum 
and stool samples. The serum sample was used to 
assess the general immunological stimulation in 
the peripheral circulation, whereas the stool sam-
ple was used to assess the local immunological 
stimulation, close to the inflamed intestine. 
In our study, we found a  higher serum IL-1ra 
concentration and a  lower IL-1ra/IL-1b ratio in 
children with active UC who had relapsed, and 
higher serum and stool IL-1b and serum IL-1ra 
concentrations in children with active UC who 
had experienced complications over the 5-year 
follow-up period, compared to the group without 
complications. We also found that serum IL-1b 
and IL-1ra concentrations were higher in the in-
active UC group with relapses during the 5-year 
follow-up period compared to the group that had 
not-relapsed.
However, in our study we did not analyze fac-
tors that potentially may provoke or influence 
the relapse in the course of the disease. During 
statistical analysis we did not find any statistical-
ly significant differences or correlations between 
relapsing and non-relapsing UC patients regard-
ing the clinical, endoscopic and histopathological 
activity of UC, disease location, disease duration, 
nutritional status or used treatment.
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To date, there have been only a few studies that 
have assessed the clinical and prognostic value of 
immunological mediators including ILs. 
Däbritz et al. studied 147 adults and 34 chil-
dren with CD and UC to investigate the use of 
a  novel marker of intestinal inflammation, neu-
trophil-derived protein S100A12. During a 3-year 
follow-up period they collected serum and stool 
samples from the patients for the assessment of 
this marker. The authors found that the concen-
trations of the S100A12 protein in the serum and 
fecal samples were correlated with other markers, 
disease activity and location of inflammatory le-
sions. Increased S100A12 levels were also asso-
ciated with an increased relapse risk with high 
sensitivity and specificity. Däbritz et al. suggested 
that this protein could be used as a marker to pre-
dict relapse in IBD patients [36].
In another study by Däbritz et al. they assessed 
the use of serum granulocyte macrophage colo-
ny-stimulating factor (GM-CSF) autoantibodies as 
a disease relapse marker in IBD. They found that 
the concentration of serum GM-CSF autoantibod-
ies was correlated with disease activity and loca-
tion, and that increased serum levels could predict 
a clinical relapse of up to 6 months [37].
A  study by Mahida et al. assessed the serum 
IL-6 concentrations in adult patients with UC or 
CD. They found elevated IL-6 concentrations in 
the CD group but not in the UC group, in which 
IL-6 concentrations were comparable to controls. 
IL-6 concentrations were correlated with activity 
markers, especially in the CD group. However, the 
patients were not followed up, and therefore the 
relationship of IL-6 concentrations with relapse 
and complications of IBD was not assessed [38].
A  prospective study by Garcia-Sanchez et al. 
on 135 adult patients with IBD in remission eval-
uated the use of systemic cytokines including 
TNF-α, IL-1b and IL-6 as predictors of IBD relapse. 
The patients were followed up after a  year, and 
30% of patients were found to have relapsed. The 
authors did not find any association between 
cytokine concentration and risk of relapse and 
therefore suggested that the serum cytokine as-
sessment had no clinical value in the prediction 
of IBD relapse [39]. In contrast to the results from 
Garcia-Sanchez et al., we found statistically signif-
icant differences between relapsing and non-re-
lapsing patients. The differences between studies 
may be explained by the different patient popula-
tion (adults vs. children) and the follow-up period 
(1 year vs. 5 years). Additionally, in our study we 
assessed the concentration of these cytokines in 
stool samples, which provided more information 
and increased the value of the study. 
To our knowledge, no previous studies have 
assessed the predictive value of the concentra-
tion of cytokines in stool samples of patients 
with IBD. Therefore, our study is the first to as-
sess the value of stool ILs as predictors of relapse 
and complications in patients with IBD. Our re-
sults suggest that the clinical determination of 
stool and serum IL concentrations have a poten-
tial use as a non-invasive method of stratifying 
the risk of relapse and complications among chil-
dren with UC.
In conclusion, clinical use of known biomarkers 
in predicting disease progression and in determi-
nation of the most efficient therapeutic strategies 
is limited [40]. None of them is sensitive or specif-
ic enough, which makes it difficult to predict the 
future disease progression of IBD [41]. Due to the 
confirmed immunological background of IBD, we 
hypothesized that immunological mediators, such 
as IL-1b and IL-1ra, could potentially be used for 
the assessment of disease activity in IBD.
The results of this study suggest that serum 
and to a lesser extend stool IL-1b and IL-1ra con-
centrations may be useful prognostic factors in 
children with active and inactive UC over a short-
term follow-up period. This could help to identify 
children who require more aggressive therapy due 
to an increased risk of relapse or complications as-
sociated with UC.
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